Blog

Early discovery and small-scale production are only part of the lifecycle of an antibody therapeutic. When a lead antibody shows promise (e.g., strong efficacy in animal models, desirable specificity), the focus shifts to manufacturability: can you produce enough of the antibody for IND-enabli

High-Throughput Recombinant Antibody Production – Gene to Antibody in 2 WeeksOnce antibody candidates are identified (whether via AbDrop™ or other methods), the next challenge is producing enough of each antibody for validation studies. This is where Biointron’s High-Throughput (HTP) Recomb

Biointron’s Antibody ABCs video series is a growing collection of concise, technical definitions designed to clarify foundational terms in antibody research and development. Each video in the series breaks down essential concepts, offering clear, concise explanations.Antibody ABCs: Antibody Formula

DOI: 10.1533/9781908818041.357Recombinant monoclonal antibodies (rAbs) are synthetic molecules produced in the laboratory to act as specific binding agents to target an antigen. In contrast to conventional monoclonal antibodies produced using hybridoma technology, rAbs are made by recombinant DNA me

In the race to develop new biologics, therapeutic antibodies stand out as one of the most successful and rapidly expanding classes of drugs. By 2025, over 200 antibody therapeutics have reached the market, with nearly 1,400 more in clinical evaluation. This boom is driven by antibodies’ high specif

DOI: 10.1186/s40364-025-00764-4 Antibody therapies have become central to oncology, providing immune-mediated, target-specific treatments for malignancies with enhanced specificity and decreased systemic toxicities. Even so, the biology of tumors—such as antig

Antibody-drug conjugates (ADCs) are biopharmaceuticals that merge the high specificity of monoclonal antibodies with the cell-killing activity of cytotoxic drugs. The antibody component targets a specific antigen on the surface of tumor cells, delivering the payload directly to diseased tissue while minimizing exposure to healthy cells. This targeted approach aims to improve therapeutic efficacy and reduce systemic toxicity compared to traditional chemotherapy.

Bispecific antibodies (BsAbs) are revolutionizing therapeutic strategies by simultaneously targeting two different antigens, offering enhanced efficacy in treating complex diseases like cancer and autoimmune disorders. As of 2025, numerous pharmaceutical and biotechnology companies are at the forefront of BsAb development, driving innovation and expanding clinical applications.

Bispecific antibodies (bsAbs) have emerged as powerful therapeutic and research tools due to their ability to simultaneously bind two distinct antigens or epitopes. This dual specificity enables novel mechanisms of action, such as redirecting immune cells to tumor sites, crosslinking

Inherited muscular disorders such as Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1) are progressive genetic diseases for which curative treatments remain elusive. Recent advances in biotechnology have brought antibody-based therapies into focus as precision tools to enhance dr

Milestones in UC treatment. DOI: 10.1177/17562848221138160 Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by inflammation of the colonic mucosa. Standard therapeutic options include aminosalicylates, corticosteroids, and

DOI: 10.1016/j.phrs.2024.107469Introduction to Antibody-Oligonucleotide Conjugates (AOCs)The increasing prevalence of cancer and the need for precise treatment modalities have accelerated the development of targeted therapies. Among these, antibody-oligonucleotide conjugates (AOCs) represent a conve